Gencellmed
Founded in 2019 as the first startup from the New Drug Division at KIRAMS, Gencellmed develops HSV-1–based oncolytic viral therapies. The company designs engineered viral vectors that selectively bind and replicate in cancer cells and deliver immune-stimulatory payloads. Lead programs are in preclinical development, including a candidate that targets EpCAM-overexpressing tumors.
Industries
N/A
Nr. of Employees
small (1-50)
Gencellmed
Room 302, Research Building #3, 75 Nowon-ro, Nowon-gu, Seoul, South Korea 01812
Patents
Recombinant herpes simplex virus having modified glycoprotein gH for retargeting and use thereof
US-12246048-B2
View DetailsRecombinant herpes simplex virus having expression cassette expressing fused protein of cancer cell-targeting domain and extracellular domain of HVEM and use thereof
US-11421017-B2
View Details
Recombinant herpes simplex virus having modified glycoprotein gH for retargeting and use thereof
US-12246048-B2
View DetailsRecombinant herpes simplex virus having expression cassette expressing fused protein of cancer cell-targeting domain and extracellular domain of HVEM and use thereof
US-11421017-B2
View DetailsProducts
GCM-101 (oncolytic HSV-1 candidate targeting EpCAM)
An HSV-1–based oncolytic virus engineered to target EpCAM-overexpressing tumor cells using adapter and glycoprotein retargeting and hTERT-driven selective replication; preclinical activity reported in ovarian and prostate cancer models and other EpCAM-high tumors.
rdGCM replication-defective HSV-1 vector platform
A replication-defective HSV-1 gene delivery platform with reported gene capacity >= 30 kb and provisions for cell-surface protein–specific targeting through glycoprotein modification.
GCM-101 (oncolytic HSV-1 candidate targeting EpCAM)
An HSV-1–based oncolytic virus engineered to target EpCAM-overexpressing tumor cells using adapter and glycoprotein retargeting and hTERT-driven selective replication; preclinical activity reported in ovarian and prostate cancer models and other EpCAM-high tumors.
rdGCM replication-defective HSV-1 vector platform
A replication-defective HSV-1 gene delivery platform with reported gene capacity >= 30 kb and provisions for cell-surface protein–specific targeting through glycoprotein modification.
Expertise Areas
- Oncolytic virus development
- Viral vector engineering (HSV-1)
- Targeted gene delivery to tumor cells
- Immuno-oncology payload engineering
Key Technologies
- HSV-1–based oncolytic vectors
- Adapter-mediated cell targeting
- Viral envelope protein engineering
- Double-targeting retargeting strategy
News & Updates
Selected for national new medicine development programs and completed a Series A financing round (reported 2021).
Multiple patents granted in Korea (gH adapter, oHSV adapter, double-targeting) and international filings related to adapter and glycoprotein retargeting.
Media coverage describing development of HSV-1–based oncolytic viruses with double-targeting and hTERT-driven replication control, and reporting preclinical intravenous efficacy.
Coverage of company founding as the first venture from the Korea Institute of Radiological & Medical Sciences and early funding interest.
Completed Series A investment (reported amount KRW 2 billion).
Selected for TIPS program and other national new medicine development projects; completion of TIPS program noted.
Selected for national new medicine development programs and completed a Series A financing round (reported 2021).
Multiple patents granted in Korea (gH adapter, oHSV adapter, double-targeting) and international filings related to adapter and glycoprotein retargeting.
Media coverage describing development of HSV-1–based oncolytic viruses with double-targeting and hTERT-driven replication control, and reporting preclinical intravenous efficacy.
Coverage of company founding as the first venture from the Korea Institute of Radiological & Medical Sciences and early funding interest.
Completed Series A investment (reported amount KRW 2 billion).
Selected for TIPS program and other national new medicine development projects; completion of TIPS program noted.